JP3867196B2 - ＴＮＦ−α産生阻害物質 - Google Patents

ＴＮＦ−α産生阻害物質 Download PDF

Info

Publication number
JP3867196B2
JP3867196B2 JP2001164523A JP2001164523A JP3867196B2 JP 3867196 B2 JP3867196 B2 JP 3867196B2 JP 2001164523 A JP2001164523 A JP 2001164523A JP 2001164523 A JP2001164523 A JP 2001164523A JP 3867196 B2 JP3867196 B2 JP 3867196B2
Authority
JP
Japan
Prior art keywords
ethyl
pyridyl
adamantyl
propyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001164523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002053555A (ja
JP2002053555A5 (https=
Inventor
正和 伴
寛 須原
正人 堀内
悟功 山本
裕志 榎本
博行 井上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to JP2001164523A priority Critical patent/JP3867196B2/ja
Publication of JP2002053555A publication Critical patent/JP2002053555A/ja
Publication of JP2002053555A5 publication Critical patent/JP2002053555A5/ja
Application granted granted Critical
Publication of JP3867196B2 publication Critical patent/JP3867196B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001164523A 2000-05-31 2001-05-31 ＴＮＦ−α産生阻害物質 Expired - Fee Related JP3867196B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001164523A JP3867196B2 (ja) 2000-05-31 2001-05-31 ＴＮＦ−α産生阻害物質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000162945 2000-05-31
JP2000-162945 2000-05-31
JP2001164523A JP3867196B2 (ja) 2000-05-31 2001-05-31 ＴＮＦ−α産生阻害物質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006140241A Division JP4482735B2 (ja) 2000-05-31 2006-05-19 ＴＮＦ−α産生阻害物質

Publications (3)

Publication Number Publication Date
JP2002053555A JP2002053555A (ja) 2002-02-19
JP2002053555A5 JP2002053555A5 (https=) 2006-07-20
JP3867196B2 true JP3867196B2 (ja) 2007-01-10

Family

ID=18666780

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001164523A Expired - Fee Related JP3867196B2 (ja) 2000-05-31 2001-05-31 ＴＮＦ−α産生阻害物質
JP2006140241A Expired - Fee Related JP4482735B2 (ja) 2000-05-31 2006-05-19 ＴＮＦ−α産生阻害物質
JP2009283085A Pending JP2010059205A (ja) 2000-05-31 2009-12-14 ＴＮＦ−α産生阻害物質
JP2009283084A Pending JP2010059204A (ja) 2000-05-31 2009-12-14 ＴＮＦ−α産生阻害物質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006140241A Expired - Fee Related JP4482735B2 (ja) 2000-05-31 2006-05-19 ＴＮＦ−α産生阻害物質
JP2009283085A Pending JP2010059205A (ja) 2000-05-31 2009-12-14 ＴＮＦ−α産生阻害物質
JP2009283084A Pending JP2010059204A (ja) 2000-05-31 2009-12-14 ＴＮＦ−α産生阻害物質

Country Status (15)

Country Link
US (5) US7098226B2 (https=)
EP (4) EP1561749B1 (https=)
JP (4) JP3867196B2 (https=)
KR (2) KR100880698B1 (https=)
CN (3) CN1284771C (https=)
AT (4) ATE481385T1 (https=)
AU (3) AU6067401A (https=)
CA (2) CA2736344A1 (https=)
CY (1) CY1107089T1 (https=)
DE (4) DE60130658T2 (https=)
DK (1) DK1302461T3 (https=)
ES (4) ES2293993T3 (https=)
NO (2) NO324472B1 (https=)
PT (1) PT1302461E (https=)
WO (1) WO2001092229A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481385T1 (de) * 2000-05-31 2010-10-15 Santen Pharmaceutical Co Ltd (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren
WO2003045367A1 (en) * 2001-11-30 2003-06-05 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
CN101404986B (zh) 2002-05-17 2011-09-28 赛奎拉公司 用于诊断和治疗感染性疾病的组合物和制药方法
US7456222B2 (en) 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
EP1670314A4 (en) 2003-09-05 2009-02-25 Sequella Inc METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
WO2005102331A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 骨粗鬆症治療剤
WO2005102332A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 変形性関節症治療剤
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006035760A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 皮膚疾患治療剤
WO2006035759A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 呼吸器疾患治療剤
WO2006043518A1 (ja) * 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. 神経疾患治療剤
JP5133702B2 (ja) * 2005-01-05 2013-01-30 アボット・ラボラトリーズ １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074244A2 (en) * 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8562629B2 (en) * 2006-10-24 2013-10-22 Arthrocare Corporation Suture device having selective needle actuation and related method
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
US20100261911A1 (en) * 2007-10-16 2010-10-14 Kenji Oki Therapeutic agent for trpv1-mediated disease
KR101702142B1 (ko) * 2008-10-22 2017-02-03 아유미 세이야쿠 가부시키가이샤 장관 흡수성을 개선하는 의약 조성물
RU2404157C1 (ru) * 2009-02-16 2010-11-20 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения n-(1-адамантилалкил)циклоалкиламинов
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
KR101231412B1 (ko) * 2009-12-29 2013-02-07 실트로닉 아게 실리콘 웨이퍼 및 그 제조 방법
CA2930584A1 (en) 2013-11-15 2015-05-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and their method of use
AU2016262572B2 (en) 2015-05-14 2020-04-30 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
EP3793546B1 (en) 2018-05-17 2025-11-19 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CN110423216B (zh) * 2019-08-26 2021-01-05 浙江工业大学 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用
WO2024084056A1 (en) * 2022-10-21 2024-04-25 Etherna Immunotherapies Nv Ionizable lipids

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2640055A (en) * 1951-01-06 1953-05-26 Warner Hudnut Inc Amides
CH509314A (de) * 1967-02-16 1971-06-30 Shimamoto Takio Verfahren zur Herstellung von Pyridinmethylcarbamaten
US3682922A (en) 1969-01-16 1972-08-08 Searle & Co N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines
US4724235A (en) 1981-05-20 1988-02-09 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia
US4597902A (en) 1981-05-20 1986-07-01 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas
US4555515A (en) * 1985-02-25 1985-11-26 Stauffer Chemical Co. Pyridylpropyl carbamates as insect repellents
US5599944A (en) * 1987-03-24 1997-02-04 Bayer Aktiengesellschaft Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
FR2664269B1 (fr) 1990-07-05 1992-10-02 Roussel Uclaf Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173506A (en) 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
AU9030691A (en) 1990-11-06 1992-05-26 Smithkline Beecham Corporation Imidazolidinone compounds
NZ242054A (en) * 1991-03-22 1993-11-25 British Tech Group Pyridine derivatives having a bridged alicyclic group; medicaments
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1995029909A1 (en) * 1994-04-29 1995-11-09 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
DE69634822T2 (de) 1995-08-22 2006-04-27 Japan Tobacco Inc. Amid-verbindungen und ihre anwendung
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
GB9526558D0 (en) * 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
JP2000516197A (ja) * 1996-01-16 2000-12-05 メルク エンド カンパニー インコーポレーテッド インテグリンレセプターアンタゴニスト
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
WO1998027069A1 (en) 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
DE59806420D1 (de) 1997-09-17 2003-01-09 Chemiefaser Lenzing Ag Verfahren zur Behandlung von Cellulosefasern
EP0903434B1 (de) 1997-09-17 2002-11-27 Lenzing Aktiengesellschaft Verfahren zur Behandlung von Cellulosefasern
JP3603177B2 (ja) 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
CN1305846C (zh) 1998-03-26 2007-03-21 参天制药株式会社 脲衍生物
CN1147469C (zh) * 1998-08-05 2004-04-28 参天制药株式会社 带有芳香族含氮杂环的新型脲衍生物
JP3472917B2 (ja) 1998-08-05 2003-12-02 参天製薬株式会社 含窒素芳香族複素環を有する新規ウレア誘導体
WO2000056725A1 (en) * 1999-03-19 2000-09-28 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'-[4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
WO2000061552A1 (en) 1999-04-07 2000-10-19 Santen Pharmaceutical Co., Ltd. N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-α PRODUCTION INHIBITOR
DE29910780U1 (de) * 1999-06-21 1999-09-16 Hahn Schickard Ges Halte- und Betätigungsvorrichtung
ATE481385T1 (de) * 2000-05-31 2010-10-15 Santen Pharmaceutical Co Ltd (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren
WO2003045367A1 (en) 2001-11-30 2003-06-05 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor

Also Published As

Publication number Publication date
JP2010059204A (ja) 2010-03-18
EP1568692B1 (en) 2010-09-15
CN1590375A (zh) 2005-03-09
US7923461B2 (en) 2011-04-12
US20080182881A1 (en) 2008-07-31
NO324472B1 (no) 2007-10-29
KR100880698B1 (ko) 2009-02-02
ATE358122T1 (de) 2007-04-15
US7345064B2 (en) 2008-03-18
JP4482735B2 (ja) 2010-06-16
CA2409741A1 (en) 2001-12-06
AU2006200864A1 (en) 2006-03-23
WO2001092229A1 (fr) 2001-12-06
KR20080093166A (ko) 2008-10-20
JP2002053555A (ja) 2002-02-19
US7491739B2 (en) 2009-02-17
NO20073371L (no) 2002-11-28
CN1432000A (zh) 2003-07-23
AU6067401A (en) 2001-12-11
CN1324012C (zh) 2007-07-04
CN1307159C (zh) 2007-03-28
CN1284771C (zh) 2006-11-15
DE60130658T2 (de) 2008-01-31
EP1302461A1 (en) 2003-04-16
US20060229342A1 (en) 2006-10-12
US20100016380A1 (en) 2010-01-21
US20060241155A1 (en) 2006-10-26
CA2736344A1 (en) 2001-12-06
EP1743885B1 (en) 2009-11-11
CN1590374A (zh) 2005-03-09
EP1568692A1 (en) 2005-08-31
DE60143098D1 (de) 2010-10-28
US20030032623A1 (en) 2003-02-13
EP1302461A4 (en) 2004-05-26
DE60127595T2 (de) 2008-01-10
NO20025718D0 (no) 2002-11-28
ATE374186T1 (de) 2007-10-15
EP1743885A3 (en) 2007-03-14
AU2006200864B2 (en) 2007-12-06
KR20030007762A (ko) 2003-01-23
ES2339141T3 (es) 2010-05-17
US7098226B2 (en) 2006-08-29
ATE448204T1 (de) 2009-11-15
ES2293993T3 (es) 2008-04-01
ES2284138T3 (es) 2007-11-01
EP1302461B1 (en) 2007-09-26
ES2353020T3 (es) 2011-02-24
JP2006213739A (ja) 2006-08-17
EP1743885A2 (en) 2007-01-17
NO20025718L (no) 2002-11-28
EP1561749B1 (en) 2007-03-28
CA2409741C (en) 2011-11-01
DE60127595D1 (de) 2007-05-10
KR100978304B1 (ko) 2010-08-26
DE60140495D1 (de) 2009-12-24
AU2001260674B2 (en) 2006-03-30
EP1561749A1 (en) 2005-08-10
PT1302461E (pt) 2007-12-13
CY1107089T1 (el) 2012-10-24
ATE481385T1 (de) 2010-10-15
JP2010059205A (ja) 2010-03-18
DK1302461T3 (da) 2008-01-28
DE60130658D1 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
JP3867196B2 (ja) ＴＮＦ−α産生阻害物質
EP1536797B1 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related comounds as neurokinin-1 (nk-1) antagonsists for the treatment of emesis, depression, anxiety and cough
JP4018545B2 (ja) Ｆｓａｄのためのｎｅｐ阻害剤としてのｎ−フェンプロピルシクロペンチル−置換グルタルアミド誘導体
JP7745630B2 (ja) Ｙａｐ／ｔａｚ－ｔｅａｄ腫瘍性タンパク質の阻害剤、その合成及び使用
JP2000515150A (ja) 置換ベンジルアミン誘導体：新規な種類の神経ペプチドｙ１特異的リガンド
JP2000515167A (ja) 基質メタロプロテアーゼ インヒビターとしてのホスフィン酸アミド
JP2004067635A (ja) Ｄｇａｔ阻害剤
JP2002538146A (ja) ジヘテロ−置換メタロプロテアーゼ阻害剤
JPWO1993015057A1 (ja) ピリジンカルボキシイミダミド化合物およびその使用
JP2691679B2 (ja) オキシム誘導体およびそれを含有する医薬品
JP2856548B2 (ja) チオナフタレン誘導体およびその製法並びにそれを含む抗アレルギー剤
JP6758374B2 (ja) Ｉｄｈ２突然変異を標的とする抗腫瘍化合物及びその使用方法
WO2024060911A1 (zh) 苯并异噻唑化合物及其药物组合物和应用
JPH0899913A (ja) 置換シクロペンタン−ジ−及び−トリオン類の利用
JP3295277B2 (ja) 抗腎疾患剤及びベンズイミダゾール誘導体
JPS6338026B2 (https=)
JPH02229168A (ja) ピラゾロン誘導体
JP2003519100A (ja) ベータ二置換メタロプロテアーゼ阻害剤
JP2024509587A (ja) Ｊａｋ媒介性障害の治療に使用するためのｌｏｒｐｕｃｉｔｉｎｉｂ
JPH0692948A (ja) 新規なアセタミド誘導体及びその用途
TW403745B (en) Novel substituted -amidinobenzene derivative and pharmaceutical compositions thereof
KR100503518B1 (ko) 2-(4-알킬-1-피페라지닐)-벤즈알데하이드 및 -벤질리데닐화합물의 제조 방법
KR20080023758A (ko) 비만 및 관련 질환의 치료를 위한 신규한 아미노산 유도체
JP2756740B2 (ja) ２−シクロヘキセノン化合物及び該化合物を有効成分とする脳機能改善薬
JPH05125038A (ja) フエノキシアルカン酸誘導体及びその製法

Legal Events

Date Code Title Description
A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20060329

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20060427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060925

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091020

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121020

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131020

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees